UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2012
AEGERION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34921 | 20-2960116 | ||
| (State or other jurisdiction of incorporation) |
(Commission File No.) |
(IRS Identification No.) | ||
| 101 Main Street, Suite 1850, Cambridge, Massachusetts | 02142 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (617) 500-7867
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
| ¨ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders.
Aegerion Pharmaceuticals, Inc. (“Aegerion”) held its Annual Meeting of Stockholders on June 5, 2012 (the “Annual Meeting”). At the Annual Meeting, Aegerion’s stockholders elected Sandford D. Smith and Paul G. Thomas as Class II directors to serve on Aegerion’s Board of Directors until Aegerion’s 2015 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. The voting results for this proposal were as follows:
| For | Withheld | Broker Non-Votes |
||||||||||
| Sandford D. Smith |
11,050,914 | 27,284 | 4,237,276 | |||||||||
| Paul G. Thomas |
11,050,914 | 27,284 | 4,237,276 | |||||||||
In addition, at the Annual Meeting, Aegerion’s stockholders voted to ratify the selection of Ernst & Young LLP as Aegerion’s independent registered public accounting firm for the fiscal year ending December 31, 2012. The voting results for this proposal were as follows:
| For | Against | Abstain | Broker Non-Votes |
|||||||||||||
| Ratification of Independent Registered Public Accounting Firm |
15,311,263 | 4,211 | 0 | 0 | ||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 7, 2012
| AEGERION PHARMACEUTICALS, INC. | ||
| By: | /s/ Anne Marie Cook | |
| Anne Marie Cook | ||
| Senior Vice President, General Counsel and Secretary | ||